Quarterly ResultAug 12, 2026, 07:47 AM
Xilio Therapeutics Q2 Net Loss $(6.4)M, Revenue $18.7M
AI Summary
Xilio Therapeutics reported a net loss of $(6.4) million for the second quarter of 2026, a substantial improvement from a net loss of $(15.8) million in the same period last year. Revenue for Q2 2026 significantly increased to $18.7 million from $8.1 million year-over-year. As of June 30, 2026, the company held $136.0 million in cash and cash equivalents, which is projected to fund operations for at least the next twelve months.
Key Highlights
- Net loss for Q2 2026 was $(6.4) million, a significant reduction from $(15.8) million in Q2 2025.
- Total revenue for Q2 2026 increased to $18.7 million, up from $8.1 million in Q2 2025.
- Net loss per share for Q2 2026 was $(0.33), compared to $(2.30) in Q2 2025.
- Cash and cash equivalents stood at $136.0 million as of June 30, 2026.
- Accumulated deficit reached $434.7 million as of June 30, 2026.
- Net cash used in operating activities for the six months ended June 30, 2026, was $(41.1) million.
- Proceeds from financing activities for the six months ended June 30, 2026, totaled $40.2 million.
- Company expects current cash to fund operations for at least 12 months.
Price Impact
More from XLO